Why Pulse Biosciences, Inc.’s (PLSE) Stock Is Up 5.29%
As of Wednesday, August 19, Pulse Biosciences, Inc.’s PLSE share price has surged by 5.29%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Cynthia McLaughlin
Jenna Brashear
Cynthia McLaughlin
Omar Beirat
Jenna Brashear
| Share Statistics | PLSE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,412.8 | $407.7 | 61% |
|
| Shares Out (Mil) | 69.2 | 41.3 | 55% |
|
| Institutional Ownership | 14.6% | 81.4% | 8% |
|
| Float (Mil) | 20.6 | 34.9 | 29% |
|
| Beta | 1.58 | 0.88 | 85% |
|
| Avg Daily Volume (000s) | 497 | 412 | 58% |
|
| Price Change (52-week) |
201.7% | 64.8% | 97% |
|
| Growth | PLSE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.8% | na |
|
| Net Income (5yr) | (7.8%) | (6.0%) | 31% |
|
| EPS (5yr) | 12.8% | 10.4% | 52 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (33.8%) | (16.2%) | 16% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.295) | ($1.105) | ($1.155) | |
| Month Ago EPS | ($0.285) | ($1.070) | ($1.090) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.240) | ($0.910) | ($0.880) | |
| Year/Year Chg | (17.1%) | 2.3% | (20.8%) | |
| Financials | PLSE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $119 | 2% |
|
| Net Income (TTM) (Mil) | ($80) | ($9) | 13% |
|
| EPS (TTM) | ($1.176) | ($0.400) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($61) | ($3) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($5) | $1 | 34% |
|
| Long-Term Debt (Q1) (Mil) | $5 | $21 | 24% |
|
| Enterprise Value (Q1) (Mil) | $2,930 | $427 | 54% |
|
| Valuation | PLSE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 33.94 | 3.06 | 98% |
|
| P/E | na | 27.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.7 | na |
|
| Ratios | PLSE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 0.3% | 58.9% | 4% |
|
| Net Margin | na | (6.9%) | na |
|
| ROA | (67.9%) | (12.7%) | 9% |
|
| ROE | (78.5%) | (13.1%) | 11% |
|
| Liabilities to Assets | 13.9% | 46.0% | 9% |
|
| F-Score | 3 | 4 | 18% |
|
Pulse Biosciences, Inc. did not pass any screens on 8/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors